BPC-157 is still a research-stage compound with limited human clinical evidence, so the only responsible way to evaluate a product like this is to separate (1) what the company discloses and can document (testing, formulation, policies) from (2) what preclinical research suggests in animals or lab settings, and (3) what remains unproven in humans
However, understanding potential risks enables informed decision-making
Both in vitro and in vivo studies in rat tendons have shown that BPC-157 promotes collateralization and increases fibroblast density in the event of injuries to tendons, ligaments and bones
Narrow support for peptides The committee's first vote signaled narrow support for adding forms of the peptide BPC-157 to the compounding list
Individuals with cancer history or concerning risk factors should discuss any peptide use with oncologists
Dosing 1 capsule 1-2 times daily on an empty stomach or as directed.